JP2011522897A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011522897A5 JP2011522897A5 JP2011513647A JP2011513647A JP2011522897A5 JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5 JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011513647 A JP2011513647 A JP 2011513647A JP 2011522897 A5 JP2011522897 A5 JP 2011522897A5
- Authority
- JP
- Japan
- Prior art keywords
- phentermine
- cancer
- formulated
- kit
- dosage form
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims 12
- 239000002552 dosage form Substances 0.000 claims 9
- 229960001277 phentermine hydrochloride Drugs 0.000 claims 7
- NCAIGTHBQTXTLR-UHFFFAOYSA-N phentermine hydrochloride Chemical compound [Cl-].CC(C)([NH3+])CC1=CC=CC=C1 NCAIGTHBQTXTLR-UHFFFAOYSA-N 0.000 claims 7
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims 6
- 229960003562 phentermine Drugs 0.000 claims 6
- 229960004394 topiramate Drugs 0.000 claims 6
- 208000008589 Obesity Diseases 0.000 claims 5
- 238000013270 controlled release Methods 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
- 150000003626 triacylglycerols Chemical class 0.000 claims 3
- 230000004580 weight loss Effects 0.000 claims 3
- 206010051055 Deep vein thrombosis Diseases 0.000 claims 2
- 206010047249 Venous thrombosis Diseases 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010021024 Hypolipidaemia Diseases 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 208000037093 Menstruation Disturbances Diseases 0.000 claims 1
- 206010027339 Menstruation irregular Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002787 Pregnancy Complications Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000037396 body weight Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000029498 hypoalphalipoproteinemia Diseases 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000004228 ovarian endometrial cancer Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000000689 peptic esophagitis Diseases 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 201000009104 prediabetes syndrome Diseases 0.000 claims 1
- 208000012113 pregnancy disease Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 208000013220 shortness of breath Diseases 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/135,953 | 2008-06-09 | ||
| US12/135,953 US20090304789A1 (en) | 2008-06-09 | 2008-06-09 | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| PCT/US2009/046805 WO2009152190A1 (en) | 2008-06-09 | 2009-06-09 | Escalating dosing regimen for effecting weight loss and treating obesity |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015102962A Division JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011522897A JP2011522897A (ja) | 2011-08-04 |
| JP2011522897A5 true JP2011522897A5 (enExample) | 2013-11-14 |
| JP5752595B2 JP5752595B2 (ja) | 2015-07-22 |
Family
ID=40863844
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513647A Active JP5752595B2 (ja) | 2008-06-09 | 2009-06-09 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇ ｄｏｓｉｎｇ ｒｅｇｉｍｅｎ） |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513646A Pending JP2011522896A (ja) | 2008-06-09 | 2009-06-09 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2015102962A Active JP6077053B2 (ja) | 2008-06-09 | 2015-05-20 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇｄｏｓｉｎｇｒｅｇｉｍｅｎ） |
| JP2015151088A Pending JP2016006085A (ja) | 2008-06-09 | 2015-07-30 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2016246871A Active JP6214750B2 (ja) | 2008-06-09 | 2016-12-20 | 低用量トピラメート／フェンテルミン組成物およびその使用方法 |
| JP2017002448A Pending JP2017105788A (ja) | 2008-06-09 | 2017-01-11 | 体重減少の達成および肥満症の治療のための漸増用量投与計画（ｅｓｃａｌａｔｉｎｇ ｄｏｓｉｎｇ ｒｅｇｉｍｅｎ） |
Country Status (18)
| Country | Link |
|---|---|
| US (12) | US20090304789A1 (enExample) |
| EP (2) | EP2317997B1 (enExample) |
| JP (6) | JP5752595B2 (enExample) |
| KR (3) | KR20110042280A (enExample) |
| CN (4) | CN104825477A (enExample) |
| AU (2) | AU2009257572C1 (enExample) |
| BR (2) | BRPI0914991A2 (enExample) |
| CA (2) | CA2727313C (enExample) |
| CL (2) | CL2010001365A1 (enExample) |
| CY (1) | CY1118103T1 (enExample) |
| DK (1) | DK2317997T3 (enExample) |
| ES (1) | ES2606041T3 (enExample) |
| HK (1) | HK1213489A1 (enExample) |
| IL (2) | IL209875A (enExample) |
| MX (2) | MX342684B (enExample) |
| PT (1) | PT2317997T (enExample) |
| WO (2) | WO2009152189A1 (enExample) |
| ZA (2) | ZA201008839B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US20090304789A1 (en) * | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US8580298B2 (en) * | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| EP2521546A4 (en) * | 2010-01-07 | 2013-06-26 | Vivus Inc | TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| BR102012004888A2 (pt) * | 2012-03-05 | 2013-10-22 | Phartrials Pesquisas Farmaceuticas Ltda | Associação de um derivado de sulfamato monossubstituído do monossacarídeo natural d-frutose (topiramato) com um anti-depressivo da classe das fenilcetonas (bupropiona) para tratamento de obesidade e das síndromes plurimetabólicas |
| IN2012DE00826A (enExample) * | 2012-03-21 | 2015-08-21 | Ranbaxy Lab Ltd | |
| CN102579367B (zh) | 2012-03-23 | 2014-03-12 | 中国人民解放军军事医学科学院毒物药物研究所 | 托吡酯缓释药物组合物、其制备方法及用途 |
| CN103316026B (zh) * | 2012-03-23 | 2016-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 含芬特明和托吡酯的联合产品及其制备方法 |
| EP2829270B1 (en) * | 2012-03-23 | 2020-11-11 | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China | Joint product containing synephrine and topiramate |
| BR102012026555B1 (pt) * | 2012-10-17 | 2022-10-04 | Phartrials Pesquisas Farmacêuticas Ltda | Processo de obtenção e composição de fármaco proveniente do quenodeoxicolato ligado a um derivado de sulfamato monossacarídeo natural d-frutose (topiramato) e a uma fenilcetona (bupropriona) para tratamento da obesidade e das síndromes plurimetabólicas |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US20140294950A1 (en) * | 2013-03-15 | 2014-10-02 | Vivus, Inc. | Methods of treating obesity in responder and non-responder populations |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| US12329902B2 (en) | 2013-08-22 | 2025-06-17 | Sipnose Ltd. | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization |
| US11471618B2 (en) | 2014-11-09 | 2022-10-18 | Sipnose Ltd. | Adjustable dosing delivery and multi sectioned drug compartment |
| US11992604B2 (en) | 2014-11-09 | 2024-05-28 | Sipnose Ltd. | Devices and methods for delivering a substance to a body cavity |
| DE202013105715U1 (de) | 2013-08-22 | 2014-02-19 | Sipnose Ltd. | Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers |
| US12594388B2 (en) | 2013-08-22 | 2026-04-07 | Aptargroup, Inc. | Device to deliver a predetermined amount of a substance to a natural orifice of the body |
| US11278682B2 (en) | 2014-11-09 | 2022-03-22 | Sipnose Ltd. | Device and method for aerosolized delivery of substance to a natural orifice of the body |
| US12491325B2 (en) | 2013-08-22 | 2025-12-09 | Aptargroup, Inc. | Drug delivery devices and methods for administering substances to a body cavity by heterogenous aerosolization for treatment of binge-eating disorders and/or obesity |
| US11116914B2 (en) | 2014-11-09 | 2021-09-14 | Sipnose Ltd. | Device and method for aerosolized delivering of substance to a natural orifice of the body |
| CA2926321C (en) | 2013-10-08 | 2023-02-28 | Vivus, Inc. | Methods of preventing progression to type 2 diabetes mellitus |
| US20150157672A1 (en) * | 2013-12-09 | 2015-06-11 | Phytology Labs, Inc. | Kits and methods for sustained weight loss |
| US10278948B1 (en) | 2015-09-03 | 2019-05-07 | Tian Xia | Method for transnasal delivery of anticonvulsant and therapeutic treatments |
| US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
| US10498398B2 (en) * | 2015-10-12 | 2019-12-03 | Walmart Apollo, Llc | Data synthesis using near field communication |
| US20170319540A1 (en) * | 2016-05-06 | 2017-11-09 | Vivus, Inc. | Methods and Compositions for the Treatment of Non-Alcoholic Steatohepatitis |
| JP7535520B2 (ja) * | 2018-12-18 | 2024-08-16 | ニュートリション アンド バイオサイエンシズ ユーエスエー １，リミティド ライアビリティ カンパニー | メチルセルロースを含む徐放性組成物 |
| CN109908165B (zh) * | 2019-04-26 | 2020-06-09 | 北京大学 | 一种含有雷公藤红素的组合物及其应用 |
| CN109999044B (zh) * | 2019-05-24 | 2020-06-09 | 北京大学 | 一种含有醉茄素a的组合物及其应用 |
| KR102199452B1 (ko) | 2019-10-17 | 2021-01-06 | 안지훈 | 퇴식처리장치 |
| DE212021000392U1 (de) * | 2020-06-04 | 2023-06-23 | Sipnose Ltd. | Arzneimittelverabreichungsvorrichtungen zum Verabreichen von Substanzen in einen Körperhohlraum durch heterogene Aerolisierung zum Behandeln von Binge-Eating-Störungen und/oder Adipositas |
| MX2023001071A (es) * | 2020-07-29 | 2023-05-12 | Allergan Pharmaceuticals Int Ltd | Tratamiento de la migraña. |
| US12046341B2 (en) | 2021-10-05 | 2024-07-23 | Bradford Rabin | Methods and systems for electronically adjusting a dosing pattern of a patient undergoing a medical regimen |
| KR20250173977A (ko) | 2024-06-04 | 2025-12-11 | 주식회사 티에치팜 | 토피라메이트를 포함하는 약물 적재 필라멘트 및 이를 사용하여 제조된 비만 예방 또는 치료용 약학 제제 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
| US4895845A (en) * | 1986-09-15 | 1990-01-23 | Seed John C | Method of assisting weight loss |
| US4792569A (en) * | 1987-08-27 | 1988-12-20 | Mcneilab, Inc. | Anticonvulsant phenethyl sulfamates |
| US5273993A (en) * | 1989-06-12 | 1993-12-28 | A. H. Robins Company, Incorporated | Compounds having one or more aminosulfonyloxy radicals useful as pharmaceuticals |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| FR2684101B1 (fr) * | 1991-11-22 | 1993-12-31 | Adir Cie | Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
| US5242942A (en) * | 1992-04-28 | 1993-09-07 | Mcneilab, Inc. | Anticonvulsant fructopyranose cyclic sulfites and sulfates |
| US5384327A (en) * | 1992-12-22 | 1995-01-24 | Mcneilab, Inc. | Anticonvulsant sorbopyranose sulfamates |
| US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
| US5498629A (en) * | 1993-12-23 | 1996-03-12 | Ortho Pharmaceutical Corporation | Anticonvulsant pseudofructopyranose sulfamates |
| US5527788A (en) * | 1994-01-18 | 1996-06-18 | Louisiana State Univ. Medical Center Foundation | Method and composition for treating obesity comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent |
| US5753694A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS) |
| US5753693A (en) * | 1996-06-28 | 1998-05-19 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder |
| EP0915697B1 (en) * | 1996-06-28 | 2002-09-18 | Ortho-McNeil Pharmaceutical, Inc. | Anticonvulsant sulfamate derivatives useful in treating obesity |
| US5900418A (en) | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| US5795895A (en) * | 1997-06-13 | 1998-08-18 | Anchors; J. Michael | Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug |
| US5990418A (en) * | 1997-07-29 | 1999-11-23 | International Business Machines Corporation | Hermetic CBGA/CCGA structure with thermal paste cooling |
| US5885616A (en) | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
| CN1182845C (zh) * | 1999-01-19 | 2005-01-05 | 奥索-麦克尼尔药品公司 | 用于治疗集束性头痛的抗惊厥剂衍生物 |
| NZ513643A (en) * | 1999-02-24 | 2005-04-29 | Univ Cincinnati | Use of sulfamate derivatives for treating impulse control disorders |
| MXPA01010221A (es) * | 1999-04-08 | 2002-03-27 | Johnson & Johnson | Derivados anticonvulsivos utiles para disminuir la presion sanguinea. |
| NZ514811A (en) * | 1999-04-08 | 2005-01-28 | Ortho Mcneil Pharm Inc | Anticonvulsant derivatives useful in reducing blood glucose levels |
| US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
| WO2000076493A1 (en) * | 1999-06-14 | 2000-12-21 | Thomas Najarian | Combination therapy for effecting weight loss and treating obesity |
| US20080103179A1 (en) * | 2006-10-27 | 2008-05-01 | Tam Peter Y | Combination Therapy |
| US7659256B2 (en) | 1999-06-14 | 2010-02-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US7674776B2 (en) | 1999-06-14 | 2010-03-09 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US20080255093A1 (en) | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US7056890B2 (en) * | 1999-06-14 | 2006-06-06 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US7553818B2 (en) | 1999-06-14 | 2009-06-30 | Vivus, Inc. | Combination therapy for effecting weight loss and treating obesity |
| US6759437B2 (en) * | 1999-10-04 | 2004-07-06 | Martin C. Hinz | Comprehensive pharmacologic therapy for treatment of obesity including cysteine |
| CA2415093A1 (en) * | 2000-07-07 | 2002-01-17 | Carlos Plata-Salaman | Anticonvulsant derivatives useful for preventing the development of type ii diabetes mellitus and syndrome x |
| CA2417304A1 (en) * | 2000-08-02 | 2002-02-07 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful for the treatment of depression |
| US20020091114A1 (en) | 2000-10-04 | 2002-07-11 | Odile Piot-Grosjean | Combination of a CB1 receptor antagonist and of sibutramine, the pharmaceutical compositions comprising them and their use in the treatment of obesity |
| DE60121988T2 (de) * | 2000-10-30 | 2007-02-15 | Ortho-Mcneil Pharmaceutical, Inc. | Kombinationstherapie mit antidiabetischen und antikonvulsiven mitteln |
| JP2005501801A (ja) * | 2001-02-02 | 2005-01-20 | オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド | フラクトピラノーススルファメートとエリスロポイエチンを含んで成る神経学的機能不全治療 |
| US20030072802A1 (en) * | 2001-10-11 | 2003-04-17 | R.T. Alamo Ventures, Inc. | Sustained release topiramate |
| US6559293B1 (en) | 2002-02-15 | 2003-05-06 | Transform Pharmaceuticals, Inc. | Topiramate sodium trihydrate |
| US20050215552A1 (en) | 2002-05-17 | 2005-09-29 | Gadde Kishore M | Method for treating obesity |
| AU2003231788B2 (en) * | 2002-05-17 | 2008-09-11 | Duke University | Method for treating obesity |
| US20040122033A1 (en) * | 2002-12-10 | 2004-06-24 | Nargund Ravi P. | Combination therapy for the treatment of obesity |
| JP2007516297A (ja) * | 2003-12-23 | 2007-06-21 | アルザ・コーポレーシヨン | 制御送達用薬剤組成物の溶解度を高くする方法および投薬形態物 |
| BRPI0506829A (pt) * | 2004-01-13 | 2007-05-29 | Univ Duke | composições de anticonvulsivo e droga antipsicótica e métodos para sua utilização para afetar perda de peso |
| BRPI0514060A (pt) | 2004-08-03 | 2008-05-27 | Orexigen Therapeutics Inc | combinação de bupropion e um segundo composto para acarretar a perda de peso |
| DK1814590T4 (da) * | 2004-11-01 | 2014-02-24 | Amylin Pharmaceuticals Llc | Behandling af obesitet og beslægtede sygdomme. |
| US7875627B2 (en) * | 2004-12-07 | 2011-01-25 | Abbott Laboratories | Thienopyridyl compounds that inhibit vanilloid receptor subtype 1 (VR1) and uses thereof |
| US20060121112A1 (en) * | 2004-12-08 | 2006-06-08 | Elan Corporation, Plc | Topiramate pharmaceutical composition |
| NZ589951A (en) | 2004-12-23 | 2012-11-30 | Arena Pharm Inc | 5HT2C receptor modulator compositions and methods of use |
| WO2006124506A2 (en) | 2005-05-13 | 2006-11-23 | Abbott Laboratories | Combination and use of drugs |
| WO2007089318A2 (en) * | 2005-11-23 | 2007-08-09 | Orexigen Therapeutics, Inc. | Compositions and methods for reducing food cravings |
| WO2007084290A2 (en) | 2006-01-12 | 2007-07-26 | Orexigen Therapeutics, Inc. | Compositions of an anticonvulsant and psychotherapeutic and methods of using the same for reversing weight gain |
| WO2008027557A2 (en) | 2006-08-31 | 2008-03-06 | Spherics, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
| FR2907550B1 (fr) | 2006-10-18 | 2009-01-16 | Renault Sas | Ligne de prelevement de gaz circulant dans un conduit de moteur a combustion interne et banc d'essais comportant une telle ligne |
| DE602007005402D1 (de) | 2006-11-09 | 2010-04-29 | Orexigen Therapeutics Inc | Mehrschichtige pharmazeutische formulierungen mit einer schnell auflösenden zwischenschicht |
| EP2394643B1 (en) * | 2006-11-17 | 2015-09-02 | Supernus Pharmaceuticals, Inc. | Sustained-release formulations of topiramate |
| US8071557B2 (en) | 2007-06-13 | 2011-12-06 | Vivus, Inc. | Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| WO2009061436A1 (en) | 2007-11-06 | 2009-05-14 | University Of Florida Research Foundation | Compound for activating 5-ht2c receptors in combination with an amphetamine compound |
| US20090304789A1 (en) | 2008-06-09 | 2009-12-10 | Thomas Najarian | Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders |
| US8580298B2 (en) | 2008-06-09 | 2013-11-12 | Vivus, Inc. | Low dose topiramate/phentermine composition and methods of use thereof |
| EP2521546A4 (en) | 2010-01-07 | 2013-06-26 | Vivus Inc | TREATMENT OF THE OBSTRUCTIVE SLEEP APNEO SYNDROME COMBINED WITH ANTIBODY ANTIBODY AND AN ADDITIONAL ACTIVE SUBSTANCE |
-
2008
- 2008-06-09 US US12/135,953 patent/US20090304789A1/en not_active Abandoned
-
2009
- 2009-06-09 EP EP09763479.4A patent/EP2317997B1/en active Active
- 2009-06-09 CN CN201510112539.0A patent/CN104825477A/zh active Pending
- 2009-06-09 MX MX2010013505A patent/MX342684B/es active IP Right Grant
- 2009-06-09 CN CN2009801303795A patent/CN102112126A/zh active Pending
- 2009-06-09 JP JP2011513647A patent/JP5752595B2/ja active Active
- 2009-06-09 KR KR1020117000416A patent/KR20110042280A/ko not_active Ceased
- 2009-06-09 JP JP2011513646A patent/JP2011522896A/ja active Pending
- 2009-06-09 CN CN201510977746.2A patent/CN105534921A/zh active Pending
- 2009-06-09 EP EP09763480A patent/EP2300002A1/en not_active Ceased
- 2009-06-09 BR BRPI0914991A patent/BRPI0914991A2/pt not_active Application Discontinuation
- 2009-06-09 KR KR1020147027268A patent/KR20140121491A/ko not_active Ceased
- 2009-06-09 KR KR1020117000417A patent/KR20110044847A/ko not_active Ceased
- 2009-06-09 AU AU2009257572A patent/AU2009257572C1/en active Active
- 2009-06-09 CA CA2727313A patent/CA2727313C/en active Active
- 2009-06-09 WO PCT/US2009/046804 patent/WO2009152189A1/en not_active Ceased
- 2009-06-09 CN CN2009801304444A patent/CN102112127A/zh active Pending
- 2009-06-09 US US12/481,548 patent/US8580299B2/en active Active
- 2009-06-09 CA CA2727319A patent/CA2727319C/en active Active
- 2009-06-09 BR BRPI0914985-6A patent/BRPI0914985B1/pt active IP Right Grant
- 2009-06-09 ES ES09763479.4T patent/ES2606041T3/es active Active
- 2009-06-09 MX MX2010013503A patent/MX2010013503A/es active IP Right Grant
- 2009-06-09 PT PT97634794T patent/PT2317997T/pt unknown
- 2009-06-09 DK DK09763479.4T patent/DK2317997T3/en active
- 2009-06-09 AU AU2009257573A patent/AU2009257573B2/en active Active
- 2009-06-09 WO PCT/US2009/046805 patent/WO2009152190A1/en not_active Ceased
-
2010
- 2010-12-07 CL CL2010001365A patent/CL2010001365A1/es unknown
- 2010-12-07 CL CL2010001366A patent/CL2010001366A1/es unknown
- 2010-12-08 ZA ZA2010/08839A patent/ZA201008839B/en unknown
- 2010-12-08 ZA ZA2010/08840A patent/ZA201008840B/en unknown
- 2010-12-09 IL IL209875A patent/IL209875A/en active IP Right Grant
- 2010-12-09 IL IL209874A patent/IL209874B/en active IP Right Grant
-
2013
- 2013-10-08 US US14/048,416 patent/US8895057B2/en active Active
-
2014
- 2014-09-24 US US14/495,250 patent/US9011906B2/en active Active
-
2015
- 2015-04-06 US US14/679,754 patent/US20150209325A1/en not_active Abandoned
- 2015-05-20 JP JP2015102962A patent/JP6077053B2/ja active Active
- 2015-07-30 JP JP2015151088A patent/JP2016006085A/ja active Pending
- 2015-10-08 US US14/878,235 patent/US20160022630A1/en not_active Abandoned
-
2016
- 2016-02-12 HK HK16101537.0A patent/HK1213489A1/zh unknown
- 2016-05-10 US US15/150,907 patent/US20160250180A1/en not_active Abandoned
- 2016-10-19 CY CY20161101053T patent/CY1118103T1/el unknown
- 2016-12-20 JP JP2016246871A patent/JP6214750B2/ja active Active
-
2017
- 2017-01-11 JP JP2017002448A patent/JP2017105788A/ja active Pending
-
2018
- 2018-12-14 US US16/220,276 patent/US20190350897A1/en not_active Abandoned
-
2020
- 2020-02-20 US US16/796,194 patent/US20200188352A1/en not_active Abandoned
-
2021
- 2021-08-23 US US17/408,881 patent/US20210379013A1/en not_active Abandoned
-
2023
- 2023-03-22 US US18/124,774 patent/US20230233521A1/en not_active Abandoned
-
2026
- 2026-02-12 US US19/538,098 patent/US20260157995A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2317997B1 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| JP2010514831A5 (enExample) | ||
| JP2012520866A5 (enExample) | ||
| US8580298B2 (en) | Low dose topiramate/phentermine composition and methods of use thereof | |
| JP2010514829A5 (enExample) | ||
| JP2009542699A5 (enExample) | ||
| JP2011527332A5 (enExample) | ||
| JP2012006970A5 (enExample) | ||
| JP2009533356A5 (enExample) | ||
| JP2011527333A5 (enExample) | ||
| JP2008515905A5 (enExample) | ||
| JP2015526458A5 (enExample) | ||
| CN111035639A (zh) | 喹啉衍生物用于治疗软组织肉瘤的方法和用途以及用于治疗软组织肉瘤的药物组合物 | |
| JP2024527023A5 (enExample) | ||
| JP2023116697A5 (enExample) | ||
| JP2010540519A5 (enExample) | ||
| JP2009503020A5 (enExample) | ||
| JP2010515682A5 (enExample) | ||
| CN101168052A (zh) | 一种防治高尿酸血症及痛风的肠溶制剂 | |
| JP2023531675A5 (enExample) | ||
| JP2011157375A5 (enExample) | ||
| JP2008526950A5 (enExample) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2013511287A5 (enExample) | ||
| JP2023547475A5 (enExample) |